Outstanding Oncology Research Award Archives

🌱EARLY ACADEMIC PURSUITS

Shan Su began her academic journey with a strong focus on clinical oncology, immersing herself in the study of treatment methodologies and therapies for various types of cancer, especially lung cancer. Early in her career, her dedication to patient-centered treatment approaches led her to explore a range of therapeutic practices, including chemotherapy, targeted therapies, and immunotherapy.

As the Chief Physician at Guangzhou Chest Hospital, Shan Su has taken on a prominent role in the field of oncology, specializing in advanced and innovative cancer treatments. Over her ten-year tenure, she has applied targeted therapy, immunotherapy, and even local microwave ablation to treat malignant tumors, focusing particularly on lung tumors. Her role involves not only treating patients but also leading clinical advancements and educating the next generation of oncology professionals.

Dr. Su’s research has paved the way in studying complex interactions between malignancies and other diseases, notably tuberculosis (TB). Recognizing a gap in the understanding of cancer patients with concurrent TB, she led a pioneering cohort study—the largest of its kind worldwide—documenting unique treatment challenges and outcomes. Currently, she is spearheading the first international clinical study investigating the effects of combining first-line chemotherapy with immunotherapy for lung cancer patients who have active pulmonary TB, with a primary focus on evaluating the safety and efficacy of these combined treatments.

Throughout her career, Dr. Su’s research has been recognized and cited by numerous peers in the medical community, underscoring her contributions to oncology and her influence on cancer research. Her work in combining immunotherapy with chemotherapy for complex cases is particularly well-regarded, with citations reflecting the growing interest and importance of her findings.

Dr. Su’s work has influenced clinical practices on a global scale. Her expertise has contributed significantly to the understanding of complex cases involving co-occurring cancer and TB, impacting treatment protocols and inspiring other researchers to explore similar areas. As a member of the International Association for the Study of Lung Cancer (IASLC), she collaborates with a network of global oncology professionals to advance knowledge and share insights into lung cancer treatment.

Looking forward, Dr. Su remains committed to advancing oncological treatments, especially for complex cases like cancer with tuberculosis. Her ongoing research projects hold great promise for improving patient outcomes and expanding treatment options, making her a pioneer in her field. Dr. Su’s legacy will likely include groundbreaking contributions to cancer therapy innovations, laying the foundation for future treatments and offering hope for patients worldwide.

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study
Authors: Li, L., Zhang, H., Xie, Y., Cen, W., Koundal, D.
Journal: Computational and Mathematical Methods in Medicine, 2022, 2022, 1475871
Assessment of anti-PD-(L)1 for patients with coexisting malignant tumor and tuberculosis classified by active, latent, and obsolete stage
Authors: Su, S., Ye, M.-F., Cai, X.-T., Huang, H.-Y., Dong, Z.-Y.
Journal: BMC Medicine, 2021, 19(1), 322
Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival
Authors: Chen, R.-L., Zhou, J.-X., Cao, Y., Wang, S.-Y., Lin, L.-Z.
Journal: Frontiers in Immunology, 2020, 11, 1933
Tumor Mutational Burden and Genomic Alterations in Chinese Small Cell Lung Cancer Measured by Whole-Exome Sequencing
Authors: Su, S., Zou, J.-J., Zeng, Y.-Y., Zhao, Z.-G., Liu, J.-X.
Journal: BioMed Research International, 2019, 2019, 6096350
Hyaluronic acid-modified selenium nanoparticles for enhancing the therapeutic efficacy of paclitaxel in lung cancer therapy
Authors: Zou, J., Su, S., Chen, Z., Xia, Y., Huang, D.
Journal: Artificial Cells, Nanomedicine and Biotechnology, 2019, 47(1), pp. 3456–3464